Cite
MLA Citation
T Yokoyama et al.. “481PUpdated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402).” Annals of oncology, vol. 30, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100098040347.0x00002d